2. Academic Validation
  3. Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State

Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State

  • Antimicrob Agents Chemother. 2016 Jul 22;60(8):4552-62. doi: 10.1128/AAC.00282-16.
Dong-Hoon Chung 1,  Jennifer E Golden 2,  Robert S Adcock 3,  Chad E Schroeder 2,  Yong-Kyu Chu 3,  Julie B Sotsky 3,  Daniel E Cramer 3,  Paula M Chilton 4,  Chisu Song 5,  Manu Anantpadma 6,  Robert A Davey 6,  Aminul I Prodhan 7,  Xinmin Yin 7,  Xiang Zhang 7
Affiliations

Affiliations

  • 1 Departments of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, USA dhchun01@louisville.edu.
  • 2 University of Kansas Specialized Chemistry Center, Lawrence, Kansas, USA.
  • 3 Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, USA.
  • 4 Departments of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.
  • 5 Division of Infectious Diseases and Northwestern HIV Translational Research Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • 6 Texas Biomedical Research Institute, San Antonio, Texas, USA.
  • 7 Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, Kentucky, USA.
PMID: 27185801 DOI: 10.1128/AAC.00282-16
Abstract

Viral emergence and reemergence underscore the importance of developing efficacious, broad-spectrum antivirals. Here, we report the discovery of tetrahydrobenzothiazole-based compound 1, a novel, broad-spectrum Antiviral lead that was optimized from a hit compound derived from a cytopathic effect (CPE)-based Antiviral screen using Venezuelan equine encephalitis virus. Compound 1 showed Antiviral activity against a broad range of RNA viruses, including alphaviruses, flaviviruses, Influenza Virus, and ebolavirus. Mechanism-of-action studies with metabolomics and molecular approaches revealed that the compound inhibits host pyrimidine synthesis and establishes an Antiviral state by inducing a variety of interferon-stimulated genes (ISGs). Notably, the induction of the ISGs by compound 1 was independent of the production of type 1 interferons. The Antiviral activity of compound 1 was cell type dependent with a robust effect observed in human cell lines and no observed Antiviral effect in mouse cell lines. Herein, we disclose tetrahydrobenzothiazole compound 1 as a novel lead for the development of a broad-spectrum, Antiviral therapeutic and as a molecular probe to study the mechanism of the induction of ISGs that are independent of type 1 interferons.

Figures
Products